Literature DB >> 1728124

Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type.

G F Stefanini1, E Prati, M C Albini, G Piccinini, S Capelli, E Castelli, M Mazzetti, G Gasbarrini.   

Abstract

Several studies on the usefulness of oral disodium cromoglycate (DSCG) in the treatment of systemic adverse reaction to foods have been performed, with less attention to gastroenterological symptoms. In the present study, we selected 101 patients with diarrheic-type irritable bowel syndrome which improved after an elimination diet and worsened after a challenge with specific food(s). All patients were then tested for 48 commercial alimentary antigens by skin prick test (SPT) and underwent 8 wk of oral DSCG (500 mg three times a day), and the results were evaluated by means of a semiquantitative subjective and objective score. We observed an improvement of the symptoms in 67% of the 74 SPT-positive patients, whereas only 41% of the 27 SPT-negative patients showed a positive response to DSCG (p less than 0.05). These data confirm the protective role of DSCG in food-dependent diarrheic-type irritable bowel syndrome with food allergy features.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1728124

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  23 in total

Review 1.  Diagnosis and management of IBS.

Authors:  Sarah Khan; Lin Chang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10       Impact factor: 46.802

Review 2.  Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia.

Authors:  Craig A Friesen; Jennifer V Schurman; Jennifer M Colombo; Susan M Abdel-Rahman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06

3.  Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.

Authors:  Hannah Jones; Laura Hargrove; Lindsey Kennedy; Fanyin Meng; Allyson Graf-Eaton; Jennifer Owens; Gianfranco Alpini; Christopher Johnson; Francesca Bernuzzi; Jennifer Demieville; Sharon DeMorrow; Pietro Invernizzi; Heather Francis
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425

4.  Mast cell degranulation induces delayed rectal allodynia in rats: role of histamine and 5-HT.

Authors:  A M Coelho; J Fioramonti; L Bueno
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 5.  Food allergy in irritable bowel syndrome: The case of non-celiac wheat sensitivity.

Authors:  Pasquale Mansueto; Alberto D'Alcamo; Aurelio Seidita; Antonio Carroccio
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

Review 6.  Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome.

Authors:  Pejman Katiraei; Gilberto Bultron
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

7.  Food intolerance and skin prick test in treated and untreated irritable bowel syndrome.

Authors:  Dae-Won Jun; Oh-Young Lee; Ho-Joo Yoon; Seok-Hwa Lee; Hang-Lak Lee; Ho-Soon Choi; Byung-Chul Yoon; Min-Ho Lee; Dong-Hoo Lee; Sang-Hoen Cho
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

8.  Irritable bowel syndrome: bacteria and inflammation--clinical relevance now.

Authors:  Robin C Spiller
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

Review 9.  Immunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature review.

Authors:  James S Pearson; Robert M Niven; Jie Meng; Sima Atarodi; Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2015-09       Impact factor: 4.409

10.  Terminal ileal mucosal mast cells in irritable bowel syndrome.

Authors:  A P Weston; W L Biddle; P S Bhatia; P B Miner
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.